Cyclerion Therapeutics (CYCN) Regains Nasdaq Compliance

Go back to Cyclerion Therapeutics (CYCN) Regains Nasdaq Compliance

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 1, 2023 4:00 PM EDT

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Cyclerion or the Company) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Cyclerion is in compliance with all applicable listing standards.

On June 1, 2022, Cyclerion was notified by Nasdaq that it was not in compliance with the... More